David Ian Bell

David Ian Bell is currently Chief Executive Officer at Biomat USA, Inc., Chief Executive Officer at Grifols Bio Supplies, Inc., President & Chief Executive Officer at Grifols Innovation & New Technologies Ltd., President & Director at Alkahest, Inc., Director at Plasma Protein Therapeutics Association since 2020, Director at BPC Plasma, Inc., Director at Theriva Biologics SL, Director at GigaGen, Inc., Chief Corporate Affairs & Legal Officer at Grifols SA since 2003, Member-Supervisory Board at Biotest GmbH & Co. KGaA since 2022, and Vice President-Corporate Operations & Development at Grifols USA, Inc. since 2013.
Former roles include Director at Aradigm Corp.
from 2013 to 2018, Director at Shanghai RAAS Blood Products Co., Ltd., Director at Singulex, Inc., Vice President-Operations & Development at Grifols, Inc., Member of the California State Bar Association, Secretary, Vice President & General Counsel at Alpha Therapeutic Corp.
from 2000 to 2003, and Partner at Knapp, Petersen & Clarke PC from 1981 to 2000.
Education includes undergraduate degree from the University of California, Irvine in 1975 and graduate degree from Southwestern Law School in 1978.